Literature DB >> 17681164

How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial.

Jeffrey M Lackner1, James Jaccard, Susan S Krasner, Leonard A Katz, Gregory D Gudleski, Edward B Blanchard.   

Abstract

BACKGROUND AND AIMS: Although multiple clinical trials support the efficacy of psychological treatments for reducing irritable bowel syndrome (IBS) symptoms, the mechanisms responsible for symptomatic improvement are unknown. One hypothesis is that psychological treatments work by alleviating comorbid psychological distress implicated in the worsening of bowel symptoms and quality of life. An alternative hypothesis assumes that changes in distress are not strictly a cause but a consequence of IBS that will decrease with symptomatic improvement.
METHODS: We evaluated these 2 hypotheses by applying structural equation modeling (SEM) to the data set of a large number (n = 147) of Rome II diagnosed participants randomized to CBT, psychoeducation, or wait list. Per Rome guidelines, the primary end point was global improvement of gastrointestinal (GI) symptoms measured 2 weeks after a 10-week regimen. Secondary end points were distress and quality of life (QOL).
RESULTS: SEM analyses lend support to a model in which CBT is associated with improvements in IBS symptoms, but that therapeutic gains do not depend on changes in patients' overall level of psychological distress. Symptom severity, but not clinical status (pain catastrophizing, predominant bowel habits, symptom duration, abuse, diagnosable psychiatric disorder) or relevant sociodemographic variables (eg, gender, age), moderated treatment outcome.
CONCLUSION: CBT has a direct effect on global IBS symptom improvement independent of its effects on distress. Improvement in IBS symptoms is associated with improvements in the QOL, which may lower distress. Symptom improvements are not moderated by variables reflecting the mental well-being of IBS patients.

Entities:  

Mesh:

Year:  2007        PMID: 17681164      PMCID: PMC2645996          DOI: 10.1053/j.gastro.2007.05.014

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  41 in total

1.  On measures of explained variance in nonrecursive structural equation models.

Authors:  P M Bentler; T Raykov
Journal:  J Appl Psychol       Date:  2000-02

Review 2.  AGA technical review on irritable bowel syndrome.

Authors:  Douglas A Drossman; Michael Camilleri; Emeran A Mayer; William E Whitehead
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

3.  Analytic methods for questions pertaining to a randomized pretest, posttest, follow-up design.

Authors:  Joseph R Rausch; Scott E Maxwell; Ken Kelley
Journal:  J Clin Child Adolesc Psychol       Date:  2003-09

Review 4.  Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?

Authors:  D A Drossman
Journal:  Am J Med       Date:  1999-11-08       Impact factor: 4.965

5.  Cognitive-behaviour therapy as a treatment for irritable bowel syndrome: a pilot study.

Authors:  P Boyce; J Gilchrist; N J Talley; D Rose
Journal:  Aust N Z J Psychiatry       Date:  2000-04       Impact factor: 5.744

6.  The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome.

Authors:  I Heymann-Mönnikes; R Arnold; I Florin; C Herda; S Melfsen; H Mönnikes
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

7.  Cognitive factors influence outcome following multidisciplinary chronic pain treatment: a replication and extension of a cross-lagged panel analysis.

Authors:  J W Burns; B Glenn; S Bruehl; R N Harden; K Lofland
Journal:  Behav Res Ther       Date:  2003-10

8.  Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.

Authors:  Douglas A Drossman; Brenda B Toner; William E Whitehead; Nicholas E Diamant; Chris B Dalton; Susan Duncan; Shelagh Emmott; Valerie Proffitt; Donna Akman; Karen Frusciante; Terry Le; Kim Meyer; Barbara Bradshaw; Kristi Mikula; Carolyn B Morris; Carlar J Blackman; Yuming Hu; Huanguang Jia; Jim Z Li; Gary G Koch; Shrikant I Bangdiwala
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

9.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.

Authors:  Francis Creed; Lakshmi Fernandes; Elspeth Guthrie; Stephen Palmer; Joy Ratcliffe; Nicholas Read; Christine Rigby; David Thompson; Barbara Tomenson
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

10.  Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome.

Authors:  Wendy M Gonsalkorale; Brenda B Toner; Peter J Whorwell
Journal:  J Psychosom Res       Date:  2004-03       Impact factor: 3.006

View more
  43 in total

1.  Therapeutic mechanisms of a mindfulness-based treatment for IBS: effects on visceral sensitivity, catastrophizing, and affective processing of pain sensations.

Authors:  Eric L Garland; Susan A Gaylord; Olafur Palsson; Keturah Faurot; J Douglas Mann; William E Whitehead
Journal:  J Behav Med       Date:  2011-12-08

2.  Medical management of irritable bowel syndrome in 2008: current and future directions.

Authors:  Martin Storr; Christopher N Andrews
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

3.  Management of unexplained symptoms in survivors of cancer.

Authors:  Michael Feuerstein; Gina L Bruns; Courtney Pollman; Briana L Todd
Journal:  J Oncol Pract       Date:  2010-11       Impact factor: 3.840

Review 4.  New treatments for irritable bowel syndrome in women.

Authors:  Mopelola A Adeyemo; Lin Chang
Journal:  Womens Health (Lond)       Date:  2008-11

5.  The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Laurie Keefer; James Jaccard; Rebecca Firth; Darren Brenner; Jason Bratten; Laura J Dunlap; Changxing Ma; Mark Byroads
Journal:  Contemp Clin Trials       Date:  2012-07-28       Impact factor: 2.226

6.  Cognitive mediators of treatment outcomes in pediatric functional abdominal pain.

Authors:  Rona L Levy; Shelby L Langer; Joan M Romano; Jennifer Labus; Lynn S Walker; Tasha B Murphy; Miranda A L van Tilburg; Lauren D Feld; Dennis L Christie; William E Whitehead
Journal:  Clin J Pain       Date:  2014-12       Impact factor: 3.442

7.  Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions.

Authors:  Monica E Jarrett; Kevin C Cain; Robert L Burr; Vicky L Hertig; Sheldon N Rosen; Margaret M Heitkemper
Journal:  Am J Gastroenterol       Date:  2009-08-18       Impact factor: 10.864

8.  Multidomain patient-reported outcomes of irritable bowel syndrome: exploring person-centered perspectives to better understand symptom severity scores.

Authors:  Jeffrey M Lackner; James Jaccard; Charles Baum
Journal:  Value Health       Date:  2012-11-30       Impact factor: 5.725

9.  Adverse childhood experiences are associated with irritable bowel syndrome and gastrointestinal symptom severity.

Authors:  S H Park; E J Videlock; W Shih; A P Presson; E A Mayer; L Chang
Journal:  Neurogastroenterol Motil       Date:  2016-04-08       Impact factor: 3.598

10.  Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial.

Authors:  Susan A Gaylord; William E Whitehead; Rebecca S Coble; Keturah R Faurot; Olafur S Palsson; Eric L Garland; William Frey; John Douglas Mann
Journal:  BMC Complement Altern Med       Date:  2009-07-28       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.